Details for New Drug Application (NDA): 208610
✉ Email this page to a colleague
NDA 208610 describes BAXDELA, which is a drug marketed by Melinta and is included in two NDAs. It is available from one supplier. There are thirteen patents protecting this drug. Additional details are available on the BAXDELA profile page.
The generic ingredient in BAXDELA is delafloxacin meglumine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the delafloxacin meglumine profile page.
The generic ingredient in BAXDELA is delafloxacin meglumine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the delafloxacin meglumine profile page.
Summary for 208610
| Tradename: | BAXDELA |
| Applicant: | Melinta |
| Ingredient: | delafloxacin meglumine |
| Patents: | 5 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 208610
Generic Entry Date for 208610*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 208610
Suppliers and Packaging for NDA: 208610
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BAXDELA | delafloxacin meglumine | TABLET;ORAL | 208610 | NDA | Melinta Therapeutics, LLC | 70842-101 | 70842-101-01 | 1 BOTTLE in 1 CARTON (70842-101-01) / 20 TABLET in 1 BOTTLE |
| BAXDELA | delafloxacin meglumine | TABLET;ORAL | 208610 | NDA | Melinta Therapeutics, LLC | 70842-101 | 70842-101-02 | 2 BLISTER PACK in 1 CARTON (70842-101-02) / 10 TABLET in 1 BLISTER PACK (70842-101-03) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 450MG BASE | ||||
| Approval Date: | Jun 19, 2017 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jun 19, 2027 | ||||||||
| Regulatory Exclusivity Use: | GENERATING ANTIBIOTIC INCENTIVES NOW | ||||||||
| Regulatory Exclusivity Expiration: | Jun 19, 2022 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | 7,728,143 | Patent Expiration: | Jun 19, 2031 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Expired US Patents for NDA 208610
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Melinta | BAXDELA | delafloxacin meglumine | TABLET;ORAL | 208610-001 | Jun 19, 2017 | 8,273,892 | ⤷ Start Trial |
| Melinta | BAXDELA | delafloxacin meglumine | TABLET;ORAL | 208610-001 | Jun 19, 2017 | 9,539,250 | ⤷ Start Trial |
| Melinta | BAXDELA | delafloxacin meglumine | TABLET;ORAL | 208610-001 | Jun 19, 2017 | 8,969,569 | ⤷ Start Trial |
| Melinta | BAXDELA | delafloxacin meglumine | TABLET;ORAL | 208610-001 | Jun 19, 2017 | 8,648,093 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
